Centre Antoine Lacassagne

The medical center is at the forefront of research in Chronic Lymphocytic Leukemia, focusing on innovative treatment combinations to improve patient outcomes. The center's studies explore the efficacy of combining oral venetoclax with intravenously infused obinutuzumab or oral acalabrutinib, aiming to reduce the risk of tumor lysis syndrome in untreated CLL patients.

• Venetoclax and Obinutuzumab Combination
• Risk Management of Tumor Lysis Syndrome

These efforts contribute significantly to understanding and managing CLL, offering new hope for patients with this condition.

Specializing in Urothelial Cancer, the center conducts pivotal trials to assess the survival benefits of sacituzumab govitecan compared to physician's choice treatments. This research is crucial for patients with metastatic or locally advanced unresectable urothelial cancer, providing insights into more effective therapeutic strategies.

• Sacituzumab Govitecan Efficacy
• Comparative Treatment Analysis

The center's work in this area is instrumental in advancing treatment options and improving patient survival rates.

The center is a leader in Non-Small Cell Lung Cancer research, focusing on maintenance therapies post-chemotherapy. Studies evaluate the efficacy of pembrolizumab, with or without pemetrexed, in prolonging progression-free survival in stage IV NSCLC patients.

• Maintenance Pembrolizumab Therapy
• Progression-Free Survival Enhancement

This research is pivotal in refining treatment protocols and enhancing the quality of life for NSCLC patients.

Focusing on Breast Cancer, the center explores the impact of advanced imaging techniques and novel drug combinations in managing metastatic cases. Research includes the use of FES PET/CT in treatment planning and the efficacy of combining durvalumab, olaparib, and fulvestrant in ER-positive, HER2-negative breast cancer.

• FES PET/CT in Treatment Planning
• Combination Therapies for Metastatic Breast Cancer

These studies are crucial for developing personalized treatment strategies and improving patient outcomes.

The center is advancing the treatment of Solid Tumors through innovative trials involving petosemtamab, both as a single agent and in combination therapies. This research aims to improve response rates and safety profiles in patients with advanced solid tumors, including colorectal cancer.

• Petosemtamab in Solid Tumors
• Combination Therapy Efficacy

These efforts are vital in expanding therapeutic options and enhancing the effectiveness of cancer treatments.

In the realm of Head and Neck Cancer, the center is pioneering research on lymphocyte-sparing radio-immunotherapy. This approach aims to optimize radiotherapy protocols and assess the benefits of all-trans retinoic acid in treating localized squamous cell carcinoma.

• Lymphocyte-Sparing Radiotherapy
• Radio-Immunotherapy Innovations

The center's work is crucial in refining treatment strategies and improving patient outcomes in head and neck cancers.